+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone



Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone



Anticancer Research 25(3a): 1719-1723



(a) To assess the expression patterns of HER2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive ductal cancer (IDC) and IDC associated with carcinoma in situ (IDC/DCIS) and (b) to determine if there is a differential expression of these molecular markers between IDC and IDC/DCIS. Paraffin-fixed breast cancer samples, diagnosed with only one histological invasive tumor (IDC (n=130), and IDC/DCIS (n=36) were analyzed by immunohistochemical means. The non-parametric Mann-Whitney and chi2 tests were used to evaluate any statistical differences between different groups. Significance was assumed at p<0.05. A significant increase of the tumor grading was observed between IDC and IDC/DCIS (p<0.05). Her2/neu amplification was demonstrated in 49.6% of IDC compared to 31% of IDC/DCIS (p<0.05). ER expression showed no statistical differences between IDC and IDC/DCIS. The PR expression was demonstrated in 71% of IDC with significantly lower intensity than IDC/DCIS (p<0.05). The Ki67 expression was significantly higher (p<0.05) in IDC cases (64%) versus IDC/DCIS (49.7%). No differences were observed between IDC and IDC/DCIS for p53 expression. We demonstrated significantly different expression patterns of Her2/neu, PR and Ki67 in IDC versus IDC/DCIS. Since these molecular markers play important roles in carcinogenesis and tumor progression, IDC/DCIS could be an important subtype of mammary invasive ductal cancer. Differences in expression of the evaluated markers might suggest a higher malignant potential of invasive carcinomas alone. The lower expression of Her2/neu and Ki67 in IDC/DCIS could implicate a less malignant behavior compared to a differentiated IDC. Additionally, these results might suggest that DCIS might be a malignant preform and the interaction with neoplastic tissue could result in an aggressive type of invasive tumor.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 012072865

Download citation: RISBibTeXText

PMID: 16033090


Related references

Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes. Journal of Cancer Research and Clinical Oncology 145(7): 1877-1886, 2019

Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade. Breast Cancer 18(4): 286-291, 2011

Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Annals of Clinical and Laboratory Science 37(2): 127-134, 2007

DCIS subtype versus IDC grade in tumours composed of ductal carcinoma in situ and invasive ductal carcinoma. Journal of Pathology 179(Suppl. ): 16A, 1996

No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer. Cancer Epidemiology Biomarkers and Prevention 10(2): 153-154, 2001

Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast. Journal of Steroid Biochemistry and Molecular Biology 114(1-2): 68-71, 2009

Magnetic resonance imaging versus mammography for diagnosing ductal carcinoma in-situ (DCIS) around invasive breast cancer. Journal of Clinical Oncology 26(15_Suppl): 1507-1507, 2016

HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 48(6): 702-707, 2006

Breast ductal carcinoma in situ with microinvasion A definition supported by a long-term study of 1401 serially sectioned ductal carcinomas 268 DCIS-MI versus 829 DCIS and versus 304 infiltrating ductal carcinomas with a predominant DCIS component. Laboratory Investigation 80(1): 19A, 2000

The evaluation of the immunoexpression of Her2÷neu oncoprotein in ductal carcinoma in situ in association with invasive ductal carcinoma of the breast. Romanian Journal of Morphology and Embryology 53(3 Suppl): 805-810, 2012

The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification. Breast Cancer Research 5(5): 254-257, 2003

Invasive ductal carcinoma accompanied by ductal carcinoma in situ (DCIS): Comparison of DCIS grade with grade of invasive component. Breast 6(3): 132-137, 1997

The Significance of Invasive Breast Cancer Associated With Ductal Carcinoma In Situ (DCIS) Compared With Cancer Without Associated DCIS. JAMA Oncology 3(5): 708-709, 2017

Increased breast density correlates with the proliferation-seeking radiotracer (99m)Tc(V)-DMSA uptake in florid epithelial hyperplasia and in mixed ductal carcinoma in situ with invasive ductal carcinoma but not in pure invasive ductal carcinoma or in mild epithelial hyperplasia. Molecular Imaging 10(5): 370-376, 2011

Ductal carcinoma in situ (DCIS) in the male breast: a morphologic study of 84 cases of pure DCIS and 30 cases of DCIS associated with invasive carcinoma--a preliminary report. Cancer 83(10): 2139-2149, 1998